ANDA 76430, held by Rising. Benazepril Hydrochloride.
As of Nov 16, 2026, ANDA 76430 (Benazepril Hydrochloride), held by Rising, was first approved by FDA on Feb 11, 2004, with 8 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 11, 2004 | Original application | Approved |
| Benazepril Hydrochloride5MG · tablet;oral | Benazepril Hydrochloride | Discontinued |
| Benazepril Hydrochloride10MG · tablet;oral | Benazepril Hydrochloride | Discontinued |
| Benazepril Hydrochloride20MG · tablet;oral | Benazepril Hydrochloride | Discontinued |
| Benazepril Hydrochloride40MG · tablet;oral | Benazepril Hydrochloride | Discontinued |
| Apr 2, 2019 | Supplement 12Labeling · Standard review | Approved | None posted |
| Nov 28, 2017 | Supplement 11Labeling · Standard review | Approved | None posted |
| Oct 29, 2015 | Supplement 10Labeling · Standard review | Approved | None posted |
| Apr 22, 2015 | Supplement 8Labeling · Standard review | Approved | None posted |
| Apr 22, 2015 | Supplement 9Labeling · Standard review | Approved | None posted |
| Nov 8, 2012 | Supplement 7Labeling · Standard review | Approved | None posted |
| Nov 30, 2011 | Supplement 6Labeling | Approved | None posted |
| Jan 15, 2008 | Supplement 5Labeling | Approved | None posted |
| Feb 11, 2004 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters